Modification to the A11 HERV-E TCR and T cell product to improve the therapeutic efficacy for ccRCC patients.

Estimated Value: $500,000
Open 11 days left MDHealthcaresolicitation
May 19, 2026
Jun 3, 2026 1:00 PM
Healthcare
solicitation
622110
...
AI Summary
This bid is for the modification of an existing A11 HERV-E TCR and T cell product to enhance its therapeutic effectiveness for patients with clear cell renal cell carcinoma (ccRCC). The government intends to sole source this requirement.
Line Items
ItemQtyUnitEst. Unit PriceEst. TotalCategory
Modification of A11 HERV-E TCR and T cell product 1 lot $500,000.00 $500,000.00 Medical
Estimated Bid Value$500,000.00

Want the full details?

Sign up free to see the agency name, 1 document, contact info, and the original bid posting link.

📎 Notice_of_Intent_to_Sole_Source.pdf View
Sign Up Free →

Related Bids

Browse More Bids

Bids in MarylandHealthcare BidsSOLICITATION BidsClosing Soon All Bids